Drug Information

Drug General Information
Drug ID
D0C1UF
Former ID
DIB016603
Drug Name
MDX-1100
Drug Type
Antibody
Indication Crohn's disease [ICD9: 555; ICD10:K50] Phase 2 [531729]
Company
Medarex
Target and Pathway
Target(s) Small inducible cytokine B10 Target Info [531729]
KEGG Pathway Cytokine-cytokine receptor interaction
Chemokine signaling pathway
Toll-like receptor signaling pathway
RIG-I-like receptor signaling pathway
Cytosolic DNA-sensing pathway
TNF signaling pathway
Influenza A
NetPath Pathway IL-7 Signaling Pathway
TSLP Signaling Pathway
TNFalpha Signaling Pathway
TWEAK Signaling Pathway
TCR Signaling Pathway
PANTHER Pathway Inflammation mediated by chemokine and cytokine signaling pathway
Pathway Interaction Database CXCR3-mediated signaling events
Reactome Chemokine receptors bind chemokines
G alpha (i) signalling events
WikiPathways Toll-like receptor signaling pathway
Type II interferon signaling (IFNG)
Spinal Cord Injury
GPCR ligand binding
GPCR downstream signaling
Regulation of toll-like receptor signaling pathway
References
Ref 531729A phase II, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of MDX-1100, a fully human anti-CXCL10 monoclonal antibody, in combination with methotrexate in patients with rheumatoid arthritis. Arthritis Rheum. 2012 Jun;64(6):1730-9.
Ref 531729A phase II, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of MDX-1100, a fully human anti-CXCL10 monoclonal antibody, in combination with methotrexate in patients with rheumatoid arthritis. Arthritis Rheum. 2012 Jun;64(6):1730-9.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.